Audit and feedback
Coming soon - due to be launched at the end of June 2022
This activity allows you to screen patients at risk of CKD and identify those with early signs of the disease.
This activity allows you to review your approach to the diagnosis and the management of CKD.
This activity allows you to optimise your prescribing for CKD, including the use of:
- angiotensin-converting enzyme (ACE) inhibitors / angiotensin II receptor blockers (ARBs) and
- sodium-glucose co-transporter-2 (SGLT2) inhibitors to treat those with CKD and type 2 diabetes.